ReviewJournal of neurology2026
Emerging insight in genetics and therapies in young-onset Parkinson's disease (YOPD): a comprehensive review.
Review in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Young-onset Parkinson's disease (YOPD), defined as Parkinson's disease (PD) with onset between 21 and 50 years of age, represents 3-7% of all PD cases. YOPD is characterized by distinct genetic profiles, unique clinical manifestations, psychosocial challenges, and treatment responses compared to late-onset PD. Genetic mutations in PARK2, PINK1, DJ-1, SNCA, LRRK2, and GBA significantly contribute to the disease pathogenesis, influencing clinical outcomes and disease progression. Clinically, YOPD patients often present with rigidity, dystonia, and early motor fluctuations, alongside heightened psychiatric manifestations, significantly impacting quality of life. Advanced therapies, such as deep brain stimulation (DBS) and continuous subcutaneous apomorphine infusion (CSAI), offer substantial clinical benefit, although data specific to YOPD remain limited. Neuroimaging advancements provide insight into structural and functional brain alterations distinct to YOPD, facilitating earlier and more accurate diagnosis. This review synthesizes current knowledge on genetics, clinical features, psychosocial impacts, neuroimaging, and therapeutic approaches, underscoring the necessity for personalized multidisciplinary management strategies for YOPD.
Indexed as
Identifiers
42247186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.